News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fate Therapeutics (FATE) Bombs in IPO Debut, Prices at Low End of Revised Range


10/1/2013 9:31:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Fate Therapeutics, an early clinical-stage biotech developing stem cell treatments for orphan diseases, raised $40 million by offering 6.7 million shares at $6, the low end of the revised range of $6 to $8. The company had initially filed to offer 4.0 million shares at a range of $14 to $16, before cutting the deal size 22% on Monday morning. Fate Therapeutics plans to list on the NASDAQ under the symbol FATE. Cowen & Company and BMO Capital Markets acted as lead managers on the deal.

Help employers find you! Check out all the jobs and post your resume.

Read at Nasdaq
Read at RTT News
Read at Street Insider


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES